WAP
MRNA icon

Wealthcare Advisory Partners’s Moderna MRNA Stock Holding History

Wealthcare Advisory Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,700
Closed -$202K – 894
2024
Q2 		$202K Buy
+1,700
New +$215K 0.01% 787
2023
Q4 		– Sell
-2,642
Closed -$273K – 761
2023
Q3 		$273K Sell
2,642
-568
-18% -$63.4K 0.01% 575
2023
Q2 		$390K Sell
3,210
-1,037
-24% -$138K 0.02% 502
2023
Q1 		$652K Sell
4,247
-1,792
-30% -$296K 0.03% 385
2022
Q4 		$1.08M Sell
6,039
-198
-3% -$32.4K 0.05% 264
2022
Q3 		$738K Sell
6,237
-503
-7% -$76.3K 0.04% 281
2022
Q2 		$963K Sell
6,740
-109
-2% -$15.6K 0.06% 212
2022
Q1 		$1.18M Sell
6,849
-1,336
-16% -$225K 0.07% 165
2021
Q4 		$2.08M Sell
8,185
-640
-7% -$187K 0.12% 102
2021
Q3 		$3.4M Buy
8,825
+113
+1% +$41.7K 0.22% 67
2021
Q2 		$2.05M Buy
8,712
+1,977
+29% +$353K 0.14% 104
2021
Q1 		$882K Buy
6,735
+4,070
+153% +$590K 0.06% 198
2020
Q4 		$278K Buy
+2,665
New +$270K 0.02% 334
2020
Q2 		– Sell
-175
Closed -$5K – 970
2020
Q1 		$5K Buy
+175
New +$4.03K ﹤0.01% 1111

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wealthcare Advisory Partners's MRNA Position: Q3 2024 in Review

Wealthcare Advisory Partners sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,700 shares — an estimated $202K sold.

Wealthcare Advisory Partners first reported a position in MRNA in Q1 2020 and held it in 14 quarters. The position peaked at $3.4M in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Wealthcare Advisory Partners reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 1,700 Moderna shares in Q3 2024, an estimated $202K.
  • Wealthcare Advisory Partners first reported a position in Moderna in Q1 2020 and held it in 14 quarters.
  • Wealthcare Advisory Partners's Moderna position peaked at $3.4M in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Wealthcare Advisory Partners's 13F filing for Q3 2024, filed 4 Nov 2024.